Haisco has been approved to conduct clinical trials of its independently developed HSK47388 tablets
August 9, 2025
Source: drugdu
123
August 7, Haisco(002653) issued an announcement that the company recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving its independently developed innovative drugClinical trials are underway for HSK47388 tablets, a Class 1 chemical drug intended for the treatment of autoimmune diseases.
According to the announcement, HSK47388 tablets demonstrated dose-dependent inhibition of inflammatory responses in preclinical studies, with good tolerability and safety, and are expected to provide a new treatment option for patients with autoimmune diseases. The company will continue to monitor the progress of this project and fulfill its corresponding information disclosure obligations.
In the first quarter of 2025, Haisco achieved revenue of 892 million yuan and net profit attributable to shareholders of the parent company of 46.61 million yuan.
https://finance.eastmoney.com/a/202508073478877223.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
